Barrett’s Esophagus in 2012: Updates in Pathogenesis, Treatment, and Surveillance
Barrett’s esophagus (BE) is the only established precursor lesion in the development of esophageal adenocarcinoma (EAC) and it increases the risk of cancer by 11-fold. It is regarded as a complication of gastroesophageal reflux disease. There is an ever-increasing body of knowledge on the pathogenesis, diagnosis, treatment, and surveillance of BE and its associated dysplasia. In this review, we summarize the latest advances in BE research and clinical practice in the past 2 years. It is critical to understand the molecular underpinnings of this disorder to comprehend the clinical outcomes of the disease. For clinical gastroenterologists, there is also continuous growth of endoscopic approaches which is daunting, and further improvements in the detection and treatment of BE and early EAC are anticipated. In the future, we may see the increased role of biomarkers, both molecular and imaging, in both diagnostic and therapeutic strategies for BE.
KeywordsBarrett’s esophagus Esophageal adenocarcinoma Biomarkers Acid reflux Obesity Endoscopic mucosal resection Radiofrequency ablation Photodynamic therapy Cryotherapy Narrow band imaging Confocal laser endomicroscopy Optical coherence tomography
Support from NCI and NIH U54 CA163004, U54 CA163059, P30 CA015083, and UL1 TR000135.
Conflict of Interest
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 13.•• Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83. This is a landmark population based study of the incidence rate of esophageal cancer in the Danish population. The study establishes that the incidence is less than a third of previously established rate. PubMedCrossRefGoogle Scholar
- 14.Burnat G, Majka J, Konturek PC. Bile acids are multifunctional modulators of the Barrett’s carcinogenesis. J Physiol Pharmacol Off J Polish Physiol Soc. 2010;61(2):185–92.Google Scholar
- 19.Kusaka G, Uno K, Iijima K, et al. The role of nitric oxide in the induction of caudal-type homeobox 2 through epidermal growth factor receptor in the development of Barrett’s esophagus. Scand J Gastroenterol 2012.Google Scholar
- 23.Leggett C, Calvin AD, Gorospe EC, et al. Obstructive sleep apnea is a risk factor for Barrett’s esophagus. Gastroenterology. 2012;142(5):S751–2.Google Scholar
- 30.• Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health Benefits and Cost Effectiveness of Endoscopic and Nonendoscopic Cytosponge Screening for Barrett’s Esophagus. Gastroenterology. 2012. Screening for Barrett's esophagus is not cost effective if done with endoscopy. This cost-effectiveness study demonstrates that a non-physician based technique like the cytosponge, screening may be worthwhile.Google Scholar
- 40.• Gupta M, Lutzke LS, Prasad GA, et al. Recurrence of intestinal metaplasia after eradication of Barrett’s esophagus with radio frequency ablation - results from a BETRNet consortium. Gastroenterology. 2012;142(5):S73. This large multicenter study of patients undergoing radiofrequency ablation found a substantial recurrence rate of intestinal metaplasia after ablation highlighting the need for surveillance after complete ablation. Google Scholar
- 44.Gross S, Zfass A, Habr F, et al. Salvage cryotherapy for Barrett’s esophagus with high grade dysplasia after RFA failure. Am J Gastroenterol. 2010;105:S23–4.Google Scholar
- 46.Gorospe EC, Timmer MR, Lutzke L, Wang KK. Cryotherapy for persistent Barrett’s dysplasia after radiofrequency ablation. The American Journal of Gastroenterology. 2012, 107(S1).Google Scholar
- 50.Sharma P, Meining AR, Coron E, et al. Real-time increased detection of neoplastic tissue in Barrett’s esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc. 2011;74(3):465–72.PubMedCrossRefGoogle Scholar
- 53.Bird-Lieberman EL, Dunn JM, Coleman HG, et al. Population-Based Study Reveals New Risk-Stratification Biomarker Panel for Barrett’s Esophagus. Gastroenterology 2012.Google Scholar
- 57.Gorospe EC TJ, Lutzke L, Brankley S, Halling K, Wang KK. Physician Satisfaction with Current Barrett’s Esophagus Surveillance and Acceptability of FISH-based Testing: A Survey of Gastroenterologists across the United States. In: DDW 2012, vol. 142. San Diego, CA; 2012: S-73.Google Scholar